2026-04-29T23:03:51Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/265062025-12-18T12:59:18Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Dao, Aiken author Kim, Hannah Yejin author Halliday, Catriona L author Oladele, Rita author Rickerts, Volker author Govender, Nelesh P author Shin, Jong-Hee author Heim, Jutta author Ford, Nathan Paul author Nahrgang, Saskia Andrea author Gigante, Valeria author Beardsley, Justin author Sati, Hatim author Morrissey, C Orla author Alffenaar, Jan-Willem author Alastruey-Izquierdo, Ana author 2024-06-27 Histoplasmosis, a significant mycosis primarily prevalent in Africa, North and South America, with emerging reports globally, poses notable health challenges, particularly in immunocompromised individuals such as people living with HIV/AIDS and organ transplant recipients. This systematic review, aimed at informing the World Health Organization's Fungal Priority Pathogens List, critically examines literature from 2011 to 2021 using PubMed and Web of Science, focusing on the incidence, mortality, morbidity, antifungal resistance, preventability, and distribution of Histoplasma. We also found a high prevalence (22%-44%) in people living with HIV, with mortality rates ranging from 21% to 53%. Despite limited data, the prevalence of histoplasmosis seems stable, with lower estimates in Europe. Complications such as central nervous system disease, pulmonary issues, and lymphoedema due to granuloma or sclerosis are noted, though their burden remains uncertain. Antifungal susceptibility varies, particularly against fluconazole (MIC: ≥32 mg/l) and caspofungin (MICs: 4-32 mg/l), while resistance to amphotericin B (MIC: 0.125-0.16 mg/l), itraconazole (MICs: 0.004-0.125 mg/l), and voriconazole (MICs: 0.004-0.125 mg/l) remains low. This review identifies critical knowledge gaps, underlining the need for robust, globally representative surveillance systems to better understand and combat this fungal threat. Dao A, Kim HY, Halliday CL, Oladele R, Rickerts V, Govender MMed NP, Shin JH, Heim J, Ford NP, Nahrgang SA, Gigante V, Beardsley J, Sati H, Morrissey CO, Alffenaar JW, Alastruey-Izquierdo A. Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list. Med Mycol. 2024 Jun 27;62(6):myae039. 10.1093/mmy/myae039 1460-2709 1369-3786 Medical mycology 38935903 https://hdl.handle.net/20.500.12105/26506 Histoplasma Antifungal resistance Clinical mycology Histoplasmosis Invasive fungal infection Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list